In summary, besides suggesting adoption of anti‐EGFR therapy as a therapeutic option in early‐stage gallbladder cancer based on ERBB2 alteration, we present the first evidence that presence of KRAS (G12V) but not KRAS (G13D) mutation may preclude such patients to respond to the treatment, similar to the clinical algorithm commonly practiced based on EGFR alteration in colorectal cancer. Here, KRAS is linked to colorectal cancer.